Changing environment leads PPD to set up in Japan
This article was originally published in Scrip
The US contract research company PPD has established a new direct presence in Japan. An office in Tokyo will provide Phase II to postmarketing clinical trial management services in response to growing demand in East Asia. There had been a significant increase in multinational studies including sites in Japan, the company said. Contrary to its past image as a slow and expensive place for clinical work, PPD's CEO Fred Eshelman said: "Japan offers competitive timelines for site start-up and patient enrolment, and the government is making major improvements to streamline drug development." These include a project to set up a national network of trial centres.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.